gamma-aminobutyric acid has been researched along with Muscle Spasticity in 69 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Muscle Spasticity: A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a free interval) followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis." | 9.09 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "To examine the efficacy of gabapentin in the treatment of spasticity and painful muscle spasms in patients with multiple sclerosis." | 9.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis." | 9.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide." | 9.06 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 7.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| "Gabapentin reduces the impairment of spasticity, compared with placebo, without the side effects of worsening concentration and fatigue." | 6.69 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "Progabide is an effective antispastic agent and its antispastic effect is not accompanied by increased motor weakness." | 6.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide." | 6.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Progabide was associated with lessened spasticity." | 6.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Behavioural assessments of tail muscle spasticity and mean arterial blood pressure responses to noxious somatic and/or visceral stimulation were used to test the effects of GBP on these abnormal reflexes." | 5.37 | Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. ( Duale, H; Kitzman, PH; Lyttle, TS; O'Dell, CR; Patel, SP; Rabchevsky, AG, 2011) |
| " Stroke Impairment Assessment Set (SIAS) was adopted to assess the whole function status after sroke, and the contents of glutamate (Glu) and gamma-aminobutyric acid (GABA) in serum and clinical efficacy were observed in the two groups." | 5.16 | [Comparative study on effects between electroacupuncture and acupuncture for spastic paralysis after stroke]. ( Chang, XR; Chen, LL; Jiang, JM; Li, L; Yue, ZH; Zhu, XS, 2012) |
| "To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis." | 5.09 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "To examine the efficacy of gabapentin in the treatment of spasticity and painful muscle spasms in patients with multiple sclerosis." | 5.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis." | 5.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide." | 5.06 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 3.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| "Gabapentin reduces the impairment of spasticity, compared with placebo, without the side effects of worsening concentration and fatigue." | 2.69 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| " Group results during the controlled trial did not reach statistical significance at the dosage used." | 2.68 | Effectiveness of gabapentin in controlling spasticity: a quantitative study. ( Graves, DE; Mueller, M; Olson, WH; Priebe, MM; Sherwood, AM, 1997) |
| "Higher doses provide greater control of spasticity, and controlled studies using higher doses are needed to evaluate gabapentin's efficacy." | 2.68 | Effectiveness of gabapentin in controlling spasticity: a quantitative study. ( Graves, DE; Mueller, M; Olson, WH; Priebe, MM; Sherwood, AM, 1997) |
| "As some patients with spasticity are either refractory to or intolerant of established medical treatments, we conducted this study to investigate the effect of gabapentin on spasticity in patients with spinal cord injury." | 2.68 | Gabapentin for the treatment of spasticity in patients with spinal cord injury. ( Gruenthal, M; Mueller, M; Olson, WH; Olson, WL; Priebe, MM; Sherwood, AM, 1997) |
| "Gabapentin or placebo was given orally in doses 400 mg three times daily for 48 h." | 2.68 | Effectiveness of gabapentin in controlling spasticity: a quantitative study. ( Graves, DE; Mueller, M; Olson, WH; Priebe, MM; Sherwood, AM, 1997) |
| "Progabide is an effective antispastic agent and its antispastic effect is not accompanied by increased motor weakness." | 2.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Progabide was associated with lessened spasticity." | 2.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide." | 2.66 | The GABA-agonist progabide for spasticity in multiple sclerosis. ( Breton, D; Krall, RL; Rudick, RA, 1987) |
| "16 patients with spasticity in a stationary phase completed the trial." | 2.65 | The clinical effect of the GABA-agonist, progabide, on spasticity. ( Mondrup, K; Pedersen, E, 1984) |
| " The median daily dosage of progabide was 24." | 2.65 | The clinical effect of the GABA-agonist, progabide, on spasticity. ( Mondrup, K; Pedersen, E, 1984) |
| " 2-week treatment periods were used; the median daily oral dosage of progabide was 24." | 2.65 | The effect of the GABA-agonist, progabide, on stretch and flexor reflexes and on voluntary power in spastic patients. ( Mondrup, K; Pedersen, E, 1984) |
| "Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| "The available studies on spasticity treatment offer some insight to guide clinical practice but are of variable methodological quality." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| "Gabapentin is a novelty, and the working mechanism of cannabis has been elucidated." | 2.46 | Spasticity: revisiting the role and the individual value of several pharmacological treatments. ( Kuks, JB; Lapeyre, E; Meijler, WJ, 2010) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "Weakness as well as spasticity due to lack of selective neuronal control causes functional impairment and additional mechanisms of compensation, retardation of motor development, secondary deformities of muscles and soft tissues due to a failure of muscle growth, subluxation/dislocation of joints, early osteoarthritis, and pain." | 2.41 | [Botulinum toxin type A in the treatment plan for cerebral palsy]. ( Strobl, W, 2001) |
| "Cerebral palsy is among the most frequent disorders of the growing locomotor apparatus during childhood." | 2.41 | [Botulinum toxin type A in the treatment plan for cerebral palsy]. ( Strobl, W, 2001) |
| "An animal model of chronic spasticity would be valuable." | 2.38 | The spastic mouse. And the search for an animal model of spasticity in human beings. ( Rang, M; Wright, J, 1990) |
| "At the cellular level, spasticity is considered to be primarily caused by the hyperexcitability of spinal α-motoneurons (MNs) within the spinal stretch reflex circuit." | 1.72 | Molecular Identification of Pro-Excitogenic Receptor and Channel Phenotypes of the Deafferented Lumbar Motoneurons in the Early Phase after SCT in Rats. ( Ji, B; Skup, M; Wojtaś, B, 2022) |
| "Spasticity impacts the quality of life of patients suffering spinal cord injury and impedes the recovery of locomotion." | 1.72 | Molecular Identification of Pro-Excitogenic Receptor and Channel Phenotypes of the Deafferented Lumbar Motoneurons in the Early Phase after SCT in Rats. ( Ji, B; Skup, M; Wojtaś, B, 2022) |
| "Waggle needling, a classical anti-spastic needling technique characterized by combination of acupuncture with joint movement, has gained increasing popularity of spasticity treatment in China." | 1.56 | Waggle needling wields preferable neuroprotective and anti-spastic effects on post-stroke spasticity rats by attenuating γ-aminobutyric acid transaminase and enhancing γ-aminobutyric acid. ( Gan, YY; Guo, MW; Li, JL; Ma, LX; Mu, JD; Qian, X; Ren, XX; Song, Y; Sun, TY; Tian, Y; Wang, JX; Yu, WY, 2020) |
| "Median subjective spasticity scores increased from 4 at baseline to 6 at lowest dose (p < 0." | 1.39 | Spasticity increases during pregabalin withdrawal. ( Baguley, IJ; Braid, JJ; Kirker, SG, 2013) |
| "Mean pre-withdrawal pregabalin dosage was 386 mg/day, decreasing to 70 mg/day at mean lowest dosage." | 1.39 | Spasticity increases during pregabalin withdrawal. ( Baguley, IJ; Braid, JJ; Kirker, SG, 2013) |
| "Behavioural assessments of tail muscle spasticity and mean arterial blood pressure responses to noxious somatic and/or visceral stimulation were used to test the effects of GBP on these abnormal reflexes." | 1.37 | Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. ( Duale, H; Kitzman, PH; Lyttle, TS; O'Dell, CR; Patel, SP; Rabchevsky, AG, 2011) |
| "Both spastic behavior and electromyography (EMG) activity were significantly decreased at 1 and 3 h post-GBP injection when compared with the activity level following administration of saline." | 1.34 | Gabapentin suppresses spasticity in the spinal cord-injured rat. ( Dwyer, MK; Kitzman, PH; Uhl, TL, 2007) |
| "Spinal cord ischemia was induced for 10 min using aortic occlusion and systemic hypotension." | 1.34 | Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells. ( Cizkova, D; Hazel, T; Hefferan, MP; Johe, K; Kakinohana, O; Kucharova, K; Marsala, M; Marsala, S, 2007) |
| "Transient spinal cord ischemia in humans can lead to the development of permanent paraplegia with prominent spasticity and rigidity." | 1.34 | Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells. ( Cizkova, D; Hazel, T; Hefferan, MP; Johe, K; Kakinohana, O; Kucharova, K; Marsala, M; Marsala, S, 2007) |
| " In addition the optimal time frame for cell grafting after ischemia and the optimal dosing of grafted cells were also studied." | 1.34 | Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells. ( Cizkova, D; Hazel, T; Hefferan, MP; Johe, K; Kakinohana, O; Kucharova, K; Marsala, M; Marsala, S, 2007) |
| "Transient spinal cord ischemia may lead to a progressive degeneration of spinal interneurons and subsequently to increased hind limb motor tone." | 1.33 | Development of GABA-sensitive spasticity and rigidity in rats after transient spinal cord ischemia: a qualitative and quantitative electrophysiological and histopathological study. ( Galik, J; Hefferan, MP; Kakinohana, M; Kakinohana, O; Marsala, J; Marsala, M; Nakamura, S; Tomori, Z; Yaksh, TL, 2006) |
| "A well known drug in the treatment of spasticity is the GABA(B) agonist Baclofen." | 1.31 | Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord. ( de Louw, AJ; de Vente, J; Steinbusch, HP; Steinbusch, HW; Troost, J; Vles, JS, 2002) |
| "Comparison of sham-operated spastic dogs and rhizotomy-treated spastic animals showed that there was a 25% decrease in the uptake of both amino acids in the rhizotomy-treated spastic group." | 1.27 | Effects of dorsal bilateral rhizotomy treatment on transmitter systems in the spinal cord of normal and spastic dogs. ( Chernet, E; Hall, PV; McBride, WJ; Sartorius, C; Shapiro, S, 1988) |
| "835 and a parallel shift of the probit-log dosage regression line to the right." | 1.27 | Delta-aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system. ( Klockgether, T; Schwarz, M; Sontag, KH; Turski, L; Wüllner, U, 1988) |
| "However, when the spasticity is severe, the systemic administration has to be increased, often without therapeutic effects but frequently with central side-effects." | 1.27 | Intrathecal application of baclofen in the treatment of spasticity. ( Rea, GL; Siegfried, J, 1987) |
| "We hypothesize that the symptoms in the spastic mutant may result from a deficiency of strychnine-sensitive (presumably glycinergic) inhibition in the spinal cord." | 1.26 | Electrophysiological studies with the spastic mutant mouse. ( Hallett, M; Heller, AH, 1982) |
| "Although somatic msucular spasticity appears to be, to some extent, due to GABA dysfunction in the spinal cord, alterations in "normal" functioning of other neurotransmitters and the loss of supraspinal control also contribute to this state." | 1.26 | Correlation of changes in the GABA-ergic system with the development of spasticity in paraplegic cats. ( Horst, WD; Naftchi, NE; Schlosser, W, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (30.43) | 18.7374 |
| 1990's | 7 (10.14) | 18.2507 |
| 2000's | 22 (31.88) | 29.6817 |
| 2010's | 13 (18.84) | 24.3611 |
| 2020's | 6 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Mu, JD | 3 |
| Ma, LX | 3 |
| Zhang, Z | 2 |
| Yu, WY | 3 |
| Sun, TY | 3 |
| Qian, X | 3 |
| Tian, Y | 3 |
| Wang, JX | 3 |
| Li, X | 1 |
| Song, X | 2 |
| Fang, L | 1 |
| Ding, J | 1 |
| Qi, L | 1 |
| Wang, Q | 1 |
| Dong, C | 1 |
| Wang, S | 1 |
| Wu, J | 1 |
| Wang, T | 1 |
| Wu, Q | 1 |
| Zhang, YD | 1 |
| Ji, B | 1 |
| Wojtaś, B | 1 |
| Skup, M | 1 |
| Song, Y | 1 |
| Gan, YY | 1 |
| Guo, MW | 1 |
| Ren, XX | 1 |
| Li, JL | 1 |
| Nardone, R | 1 |
| Sebastianelli, L | 1 |
| Brigo, F | 1 |
| Golaszewski, S | 1 |
| Trinka, E | 1 |
| Pucks-Faes, E | 1 |
| Saltuari, L | 1 |
| Versace, V | 1 |
| Kopach, O | 1 |
| Medvediev, V | 1 |
| Krotov, V | 1 |
| Borisyuk, A | 1 |
| Tsymbaliuk, V | 1 |
| Voitenko, N | 1 |
| Revol, B | 1 |
| Jullian-Desayes, I | 1 |
| Bailly, S | 1 |
| Mallaret, M | 1 |
| Tamisier, R | 1 |
| Agier, MS | 1 |
| Lador, F | 1 |
| Joyeux-Faure, M | 1 |
| Pépin, JL | 1 |
| Liu, C | 1 |
| Li, R | 1 |
| Feng, X | 1 |
| Trojano, M | 1 |
| Otero-Romero, S | 1 |
| Sastre-Garriga, J | 1 |
| Comi, G | 1 |
| Hartung, HP | 1 |
| Soelberg Sørensen, P | 1 |
| Thompson, AJ | 1 |
| Vermersch, P | 1 |
| Gold, R | 1 |
| Montalban, X | 1 |
| Heetla, HW | 1 |
| Staal, MJ | 1 |
| Kliphuis, C | 1 |
| van Laar, T | 1 |
| Boulenguez, P | 2 |
| Liabeuf, S | 2 |
| Bos, R | 1 |
| Bras, H | 1 |
| Jean-Xavier, C | 1 |
| Brocard, C | 1 |
| Stil, A | 1 |
| Darbon, P | 1 |
| Cattaert, D | 1 |
| Delpire, E | 1 |
| Marsala, M | 3 |
| Vinay, L | 2 |
| Edgerton, VR | 1 |
| Roy, RR | 1 |
| Rabchevsky, AG | 1 |
| Patel, SP | 1 |
| Duale, H | 1 |
| Lyttle, TS | 1 |
| O'Dell, CR | 1 |
| Kitzman, PH | 2 |
| Lapeyre, E | 1 |
| Kuks, JB | 1 |
| Meijler, WJ | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Yue, ZH | 1 |
| Li, L | 1 |
| Chang, XR | 1 |
| Jiang, JM | 1 |
| Chen, LL | 1 |
| Zhu, XS | 1 |
| Braid, JJ | 1 |
| Kirker, SG | 2 |
| Baguley, IJ | 1 |
| Arvio, M | 1 |
| Merikanto, J | 1 |
| Zafonte, R | 1 |
| Lombard, L | 1 |
| Elovic, E | 1 |
| Strobl, W | 1 |
| Formica, A | 1 |
| Verger, K | 1 |
| Sol, JM | 1 |
| Morralla, C | 1 |
| Economides, JR | 1 |
| Horton, JC | 1 |
| Wong, VC | 1 |
| Lam, CW | 1 |
| Fung, CW | 1 |
| Olaizola, I | 1 |
| Ellger, T | 1 |
| Young, P | 1 |
| Bösebeck, F | 1 |
| Evers, S | 1 |
| Kellinghaus, C | 1 |
| Kakinohana, O | 2 |
| Hefferan, MP | 2 |
| Nakamura, S | 1 |
| Kakinohana, M | 1 |
| Galik, J | 1 |
| Tomori, Z | 1 |
| Marsala, J | 1 |
| Yaksh, TL | 1 |
| Cizkova, D | 1 |
| Kucharova, K | 1 |
| Marsala, S | 1 |
| Johe, K | 1 |
| Hazel, T | 1 |
| Bradley, LJ | 1 |
| Uhl, TL | 1 |
| Dwyer, MK | 1 |
| Hattan, E | 1 |
| Angle, MR | 1 |
| Chalk, C | 1 |
| Vernino, S | 1 |
| McEvoy, K | 1 |
| Muller, E | 1 |
| Le Corronc, H | 1 |
| Scain, AL | 1 |
| Triller, A | 1 |
| Legendre, P | 1 |
| Desmedt, JE | 1 |
| Mondrup, K | 2 |
| Pedersen, E | 2 |
| Abbott, RJ | 1 |
| Currie, S | 1 |
| Howe, JG | 1 |
| Sumner, DW | 1 |
| Heller, AH | 1 |
| Hallett, M | 1 |
| Biscoe, TJ | 2 |
| Fry, JP | 1 |
| Priebe, MM | 2 |
| Sherwood, AM | 2 |
| Graves, DE | 1 |
| Mueller, M | 2 |
| Olson, WH | 3 |
| Mueller, ME | 1 |
| Gruenthal, M | 2 |
| Olson, WL | 2 |
| Cutter, NC | 1 |
| Scott, DD | 1 |
| Johnson, JC | 1 |
| Whiteneck, G | 1 |
| Mertens, P | 1 |
| Ghaemmaghami, C | 1 |
| Bert, L | 1 |
| Perret-Liaudet, A | 1 |
| Sindou, M | 1 |
| Renaud, B | 1 |
| de Carvalho, M | 1 |
| Francisco, GE | 1 |
| Kothari, S | 1 |
| Huls, C | 1 |
| de Louw, AJ | 1 |
| de Vente, J | 1 |
| Steinbusch, HP | 1 |
| Steinbusch, HW | 1 |
| Troost, J | 1 |
| Vles, JS | 1 |
| Schapiro, RT | 1 |
| Rösche, J | 1 |
| Hall, PV | 3 |
| Smith, JE | 2 |
| Campbell, RL | 2 |
| Felten, DL | 1 |
| Aprison, MH | 2 |
| Naftchi, NE | 1 |
| Schlosser, W | 1 |
| Horst, WD | 1 |
| Chatterjee, S | 1 |
| Hechtman, P | 1 |
| Duma-Drzewińska, A | 1 |
| Kiwerski, J | 1 |
| Makowski, J | 1 |
| Jones, AR | 1 |
| Fodstad, H | 1 |
| Ljunggren, BC | 1 |
| Turski, L | 3 |
| Klockgether, T | 2 |
| Turski, WA | 1 |
| Schwartz, M | 1 |
| Sontag, KH | 3 |
| Grant, SM | 1 |
| Heel, RC | 1 |
| Wright, J | 1 |
| Rang, M | 1 |
| Davidoff, RA | 1 |
| Yu, YB | 1 |
| Duchen, MR | 1 |
| McBride, WJ | 1 |
| Shapiro, S | 1 |
| Chernet, E | 1 |
| Sartorius, C | 1 |
| Bergmann, KJ | 1 |
| Ikonomidou-Turski, C | 1 |
| Schwarz, M | 2 |
| Wüllner, U | 1 |
| Siegfried, J | 1 |
| Rea, GL | 1 |
| Rudick, RA | 1 |
| Breton, D | 1 |
| Krall, RL | 1 |
| Garabedian-Ruffalo, SM | 1 |
| Ruffalo, RL | 1 |
| Knutsson, E | 1 |
| Lindblom, U | 1 |
| Mårtensson, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury[NCT00223873] | 30 participants | Interventional | 2002-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for gamma-aminobutyric acid and Muscle Spasticity
| Article | Year |
|---|---|
Effects of intrathecal baclofen therapy in subjects with disorders of consciousness: a reappraisal.
Topics: Baclofen; Consciousness; gamma-Aminobutyric Acid; Humans; Injections, Spinal; Muscle Relaxants, Cent | 2020 |
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
Spasticity: revisiting the role and the individual value of several pharmacological treatments.
Topics: Amines; Baclofen; Botulinum Toxins; Calcium Channel Blockers; Clonidine; Cyclohexanecarboxylic Acids | 2010 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
Antispasticity medications: uses and limitations of enteral therapy.
Topics: 4-Aminopyridine; Acetates; Adrenergic alpha-Agonists; Amines; Baclofen; Benzodiazepines; Cyclohexane | 2004 |
[Botulinum toxin type A in the treatment plan for cerebral palsy].
Topics: Activities of Daily Living; Adolescent; Adult; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; C | 2001 |
GABA agonists and gabapentin for spastic hypertonia.
Topics: Acetates; Amines; Animals; Anticonvulsants; Baclofen; Benzodiazepines; Cyclohexanecarboxylic Acids; | 2001 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
The spastic mouse. And the search for an animal model of spasticity in human beings.
Topics: Animals; Cerebral Palsy; Disease Models, Animal; Electric Stimulation; gamma-Aminobutyric Acid; Huma | 1990 |
Antispasticity drugs: mechanisms of action.
Topics: Adrenergic alpha-Antagonists; Animals; Anticonvulsants; Baclofen; Benzodiazepines; Central Nervous S | 1985 |
Progabide: a new GABA-mimetic agent in clinical use.
Topics: Anticonvulsants; Brain Chemistry; Chemical Phenomena; Chemistry; Epilepsy; gamma-Aminobutyric Acid; | 1985 |
10 trials available for gamma-aminobutyric acid and Muscle Spasticity
| Article | Year |
|---|---|
[Comparative study on effects between electroacupuncture and acupuncture for spastic paralysis after stroke].
Topics: Acupuncture Therapy; Electroacupuncture; gamma-Aminobutyric Acid; Glutamic Acid; Muscle Spasticity; | 2012 |
[Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial].
Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gamma-Ami | 2005 |
The effect of the GABA-agonist, progabide, on stretch and flexor reflexes and on voluntary power in spastic patients.
Topics: Achilles Tendon; Adult; Clinical Trials as Topic; Electromyography; Female; gamma-Aminobutyric Acid; | 1984 |
The clinical effect of the GABA-agonist, progabide, on spasticity.
Topics: Adult; Arm; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Female; gamma-Aminobutyric Acid | 1984 |
Effectiveness of gabapentin in controlling spasticity: a quantitative study.
Topics: Acetates; Adult; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1997 |
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acid | 1997 |
Gabapentin for the treatment of spasticity in patients with spinal cord injury.
Topics: Acetates; Administration, Oral; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarbo | 1997 |
Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cross-Over Studies; C | 2000 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
The GABA-agonist progabide for spasticity in multiple sclerosis.
Topics: Adult; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Multiple Scleros | 1987 |
48 other studies available for gamma-aminobutyric acid and Muscle Spasticity
| Article | Year |
|---|---|
Acupuncture alleviates spinal hyperreflexia and motor dysfunction in post-ischemic stroke rats with spastic hypertonia via KCC2-mediated spinal GABA
Topics: Acupuncture Therapy; Animals; gamma-Aminobutyric Acid; Humans; Ischemic Stroke; Muscle Hypertonia; M | 2022 |
Body Weight-Supported Treadmill Training Ameliorates Motoneuronal Hyperexcitability by Increasing GAD-65/67 and KCC2 Expression via TrkB Signaling in Rats with Incomplete Spinal Cord Injury.
Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid; Immunoglobulin G; | 2022 |
Acupuncture improves the structure of spastic muscle and decreases spasticity by enhancing GABA, KCC2, and GABAAγ2 in the brainstem in rats after ischemic stroke.
Topics: Acupuncture Therapy; Animals; Brain Stem; gamma-Aminobutyric Acid; Infarction, Middle Cerebral Arter | 2022 |
Molecular Identification of Pro-Excitogenic Receptor and Channel Phenotypes of the Deafferented Lumbar Motoneurons in the Early Phase after SCT in Rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Chlorides; gamma-Aminobutyric Aci | 2022 |
Waggle needling wields preferable neuroprotective and anti-spastic effects on post-stroke spasticity rats by attenuating γ-aminobutyric acid transaminase and enhancing γ-aminobutyric acid.
Topics: 4-Aminobutyrate Transaminase; Acupuncture Therapy; Animals; Brain Ischemia; gamma-Aminobutyric Acid; | 2020 |
Opposite, bidirectional shifts in excitation and inhibition in specific types of dorsal horn interneurons are associated with spasticity and pain post-SCI.
Topics: Action Potentials; Animals; Chronic Pain; gamma-Aminobutyric Acid; Glycine; Interneurons; Male; Musc | 2017 |
Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Alcoholism; Apnea; Baclofen; Database | 2018 |
Effect of catgut implantation at acupoints on GABA(B) and mGluR1 expressions in brain stem of rats with spasticity after stroke. .
Topics: Acupuncture Points; Acupuncture Therapy; Animals; Brain Stem; Catgut; Disease Models, Animal; gamma- | 2014 |
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli | 2016 |
The incidence and management of tolerance in intrathecal baclofen therapy.
Topics: Adolescent; Adult; Aged; Baclofen; Cohort Studies; Dose-Response Relationship, Drug; Drug Tolerance; | 2009 |
Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury.
Topics: Animals; Blotting, Western; Brain-Derived Neurotrophic Factor; Carboxylic Acids; Chloride Channels; | 2010 |
Spasticity: a switch from inhibition to excitation.
Topics: Animals; Chloride Channels; Down-Regulation; gamma-Aminobutyric Acid; K Cl- Cotransporters; Membrane | 2010 |
Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury.
Topics: Amines; Animals; Autonomic Dysreflexia; Cyclohexanecarboxylic Acids; Disease Models, Animal; Female; | 2011 |
[Reduced neuronal inhibition and spasticity following spinal cord injury].
Topics: Animals; Brain-Derived Neurotrophic Factor; Chlorides; gamma-Aminobutyric Acid; Glycine; H-Reflex; H | 2011 |
Spasticity increases during pregabalin withdrawal.
Topics: Analgesics; Anticonvulsants; Brain Injuries; Cerebral Palsy; Drug Administration Schedule; Female; g | 2013 |
[A relief from neural pain--gabapentin helped against hip ache in a girl with cerebral palsy].
Topics: Acetates; Adolescent; Amines; Analgesics; Arthralgia; Cerebral Palsy; Cyclohexanecarboxylic Acids; F | 2001 |
Eye movement abnormalities in stiff person syndrome.
Topics: Adult; Atrophy; Brain Stem; Cerebellar Diseases; Cerebellum; Female; gamma-Aminobutyric Acid; Glutam | 2005 |
Stiff child syndrome with mutation of DYT1 gene.
Topics: Asian People; Autoantibodies; Child; Disease Progression; DNA Mutational Analysis; Dystonia; GABA Ag | 2005 |
Pregabalin-associated acute psychosis and epileptiform EEG-changes.
Topics: Acute Disease; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; Fem | 2006 |
Development of GABA-sensitive spasticity and rigidity in rats after transient spinal cord ischemia: a qualitative and quantitative electrophysiological and histopathological study.
Topics: Acetyltransferases; Analysis of Variance; Animals; Baclofen; Dose-Response Relationship, Radiation; | 2006 |
Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells.
Topics: Adult; Animals; Astrocytes; Cell Proliferation; Cell Survival; Cells, Cultured; Evoked Potentials, M | 2007 |
Pregabalin in the treatment of spasticity: a retrospective case series.
Topics: Adult; Aged; Anticonvulsants; Cohort Studies; Female; gamma-Aminobutyric Acid; Humans; Male; Middle | 2008 |
Gabapentin suppresses spasticity in the spinal cord-injured rat.
Topics: Amines; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Cross-Over Studies; Cycloh | 2007 |
Unexpected benefit of propofol in stiff-person syndrome.
Topics: Aged; Autoantibodies; Baclofen; Diazepam; Drug Resistance; Female; GABA Agonists; GABA-A Receptor Ag | 2008 |
Propofol for stiff-person syndrome: learning new tricks from an old dog.
Topics: Aged; Autoantibodies; Baclofen; Diazepam; Drug Resistance; Female; GABA Agonists; GABA-A Receptor Ag | 2008 |
Despite GABAergic neurotransmission, GABAergic innervation does not compensate for the defect in glycine receptor postsynaptic aggregation in spastic mice.
Topics: Aging; Animals; Cell Differentiation; gamma-Aminobutyric Acid; Hypoglossal Nerve; Medulla Oblongata; | 2008 |
Mechanisms of vibration-induced inhibition or potentiation: tonic vibration reflex and vibration paradox in man.
Topics: Afferent Pathways; Extremities; gamma-Aminobutyric Acid; H-Reflex; Humans; Masseter Muscle; Mechanor | 1983 |
Cerebrospinal fluid gamma-aminobutyric acid in spasmodic torticollis.
Topics: Female; gamma-Aminobutyric Acid; Humans; Male; Muscle Spasticity; Torticollis | 1983 |
Electrophysiological studies with the spastic mutant mouse.
Topics: Animals; Electromyography; Forelimb; gamma-Aminobutyric Acid; Hindlimb; Mice; Mice, Inbred C57BL; Mi | 1982 |
Some pharmacological studies on the spastic mouse.
Topics: Animals; Anticonvulsants; Benzodiazepines; Electromyography; Female; gamma-Aminobutyric Acid; Male; | 1982 |
Amino acids in spinal dorsal horn of patients during surgery for neuropathic pain or spasticity.
Topics: Amino Acids; Aspartic Acid; Chromatography, High Pressure Liquid; Extracellular Space; Feasibility S | 2000 |
Gabapentin for the treatment of spasticity in patients with amyotrophic lateral sclerosis.
Topics: Acetates; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Hu | 2001 |
Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord.
Topics: Aging; Animals; Atrial Natriuretic Factor; Baclofen; Cervical Vertebrae; Cyclic GMP; GABA Agonists; | 2002 |
Treatment of spasticity.
Topics: Acetates; Amines; Aminopyridines; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Clonidine; Cy | 2002 |
Neurochemical correlates of spasticity.
Topics: Animals; Aspartic Acid; Dogs; Female; gamma-Aminobutyric Acid; Glutamates; Glycine; Muscle Spasticit | 1976 |
Correlation of changes in the GABA-ergic system with the development of spasticity in paraplegic cats.
Topics: Afferent Pathways; Animals; Cats; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Kinetics | 1979 |
Gamma-aminobutyric acid metabolism in brain homogenates of the spastic mouse.
Topics: Aminobutyrates; Animals; Brain; Crosses, Genetic; Female; gamma-Aminobutyric Acid; Heterozygote; Hom | 1977 |
[Lioresal in the treatment of spasticity].
Topics: Adolescent; Adult; Aged; Aminobutyrates; Baclofen; Drug Evaluation; Female; gamma-Aminobutyric Acid; | 1976 |
Levels of gamma-aminobutyric acid in the dorsal grey lumbar spinal cord during the development of experimental spinal spasticity.
Topics: Aminobutyrates; Animals; Cordotomy; Disease Models, Animal; Dogs; gamma-Aminobutyric Acid; Muscle Sp | 1976 |
Baclofen and carbamazepine in supraspinal spasticity.
Topics: Administration, Oral; Adult; Baclofen; Brain Injuries; Carbamazepine; Drug Therapy, Combination; Fem | 1991 |
The entopeduncular nucleus regulates muscle tone in genetically spastic rats: role of substance P and gamma-aminobutyric acid.
Topics: Animals; Female; gamma-Aminobutyric Acid; Globus Pallidus; Male; Muscimol; Muscle Spasticity; Muscle | 1990 |
Primary afferent terminal excitability in the normal and spastic mutant mouse spinal cord.
Topics: Animals; Anti-Anxiety Agents; Baclofen; Benzodiazepines; Bicuculline; Electric Stimulation; gamma-Am | 1987 |
Effects of dorsal bilateral rhizotomy treatment on transmitter systems in the spinal cord of normal and spastic dogs.
Topics: Animals; Dogs; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Kinetics; Muscle Spastici | 1988 |
Muscle relaxant action of phenobarbitone in genetically spastic rats: an electromyographic study.
Topics: Animals; Female; gamma-Aminobutyric Acid; Male; Muscle Spasticity; Muscle Tonus; Neuromuscular Block | 1986 |
Delta-aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system.
Topics: Animals; Baclofen; Bicuculline; Drug Antagonism; Electric Stimulation; Female; gamma-Aminobutyric Ac | 1988 |
Intrathecal application of baclofen in the treatment of spasticity.
Topics: Adolescent; Adult; Baclofen; Female; gamma-Aminobutyric Acid; Humans; Injections, Spinal; Male; Midd | 1987 |
Adverse effects secondary to baclofen withdrawal.
Topics: Adult; Baclofen; Female; gamma-Aminobutyric Acid; Hallucinations; Humans; Intestinal Absorption; Mus | 1985 |
Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis.
Topics: Adolescent; Adult; Aged; Aminobutyrates; Cold Temperature; Female; gamma-Aminobutyric Acid; Humans; | 1974 |